Thymosin Beta-4 (TB-500)
Wellness
In plain English
Thymosin beta-4 is a naturally occurring peptide involved in cell movement and tissue repair; the injectable research version is often sold as "TB-500." It is promoted for wound healing, tendon/muscle recovery, and eye-surface healing. It showed promise in animal studies and some early human wound and eye trials, but it is not an FDA-approved drug, and large trials proving benefit for musculoskeletal recovery are lacking.
The science
Thymosin beta-4 is a 43-amino-acid actin-sequestering peptide that promotes cell migration, angiogenesis, and anti-inflammatory/regenerative responses. Preclinical work established accelerated dermal wound healing (Malinda et al., 1999) and cardiac repair via integrin-linked kinase activation (Bock-Marquette et al., Nature 2004). It advanced to phase 2 human trials for chronic dermal wounds (venous stasis and pressure ulcers) with signals of faster healing (reviewed by Treadwell et al., 2012). Robust human evidence for the popular "TB-500" musculoskeletal-recovery use is lacking, and the compound is not FDA-approved. It is commonly compounded with BPC-157.
References
- Malinda KM et al., J Invest Dermatol 1999
- Bock-Marquette I et al., Nature 2004
- Treadwell T et al., Ann N Y Acad Sci 2012 (preclinical + phase 2 summary)